NASDAQ:SCPH

scPharmaceuticals (SCPH) Stock Forecast, Price & News

$7.12

+0.11 (+1.57%)

(As of 09/29/2023 ET)

Compare

Today's Range: $6.85
▼
$7.15
50-Day Range: $7.00
▼
$8.46
52-Week Range: $3.68
▼
$12.75

Volume: 180,358 shs
Average Volume: 418,433 shs
Market Capitalization: $255.32 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $19.29

scPharmaceuticals MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 170.9% Upside
$19.29 Price Target
Short Interest: Bearish
29.17% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.49
Upright™ Environmental Score
News Sentiment: 1.38
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.40) to ($1.10) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.06 out of 5 stars

Medical Sector

536th out of 972 stocks

Pharmaceutical Preparations Industry

249th out of 451 stocks

3.5

Analyst's Opinion

Consensus Rating
scPharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $19.29, scPharmaceuticals has a forecasted upside of 170.9% from its current price of $7.12.
Amount of Analyst Coverage
scPharmaceuticals has only been the subject of 2 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
29.17% of the float of scPharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
scPharmaceuticals has a short interest ratio ("days to cover") of 23.6, which indicates bearish sentiment.
Change versus previous month
Short interest in scPharmaceuticals has recently increased by 2.38%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
scPharmaceuticals does not currently pay a dividend.
Dividend Growth
scPharmaceuticals does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
scPharmaceuticals has received a 75.76% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physiological diseases " product. See details.
Environmental Sustainability
The Environmental Impact score for scPharmaceuticals is -0.49.

2.4

News and Social Media Coverage

News Sentiment
scPharmaceuticals has a news sentiment score of 1.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for scPharmaceuticals this week, compared to 2 articles on an average week.
MarketBeat Follows
Only 1 people have added scPharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, scPharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.68% of the stock of scPharmaceuticals is held by insiders.
Percentage Held by Institutions
79.60% of the stock of scPharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for scPharmaceuticals are expected to grow in the coming year, from ($1.40) to ($1.10) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of scPharmaceuticals is -5.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of scPharmaceuticals is -5.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
scPharmaceuticals has a P/B Ratio of 3.37. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About scPharmaceuticals (NASDAQ:SCPH) Stock

scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion in patients with heart failure. Its product pipeline also includes scCeftriaxone, an antibiotic to treat infections caused by gram-positive and gram-negative organisms; and scCarbapenem program, an antibiotic for treating infections caused by gram-negative organisms. The company has a development agreement with West Pharmaceutical Services, Inc. for development of single use SmartDose device. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts.

SCPH Price History

30 days | 90 days | 365 days | Advanced Chart

SCPH Stock News Headlines

September 27, 2023 | msn.com

scPharmaceuticals: Furoscix, Charting A Bright Future With FDA's Nod For CKD

September 21, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Henry Schein (HSIC) and scPharmaceuticals (SCPH)

September 29, 2023 | Chaikin Analytics (Ad)

His system isolated NVIDIA - Here's His Next Buy.

Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.

September 19, 2023 | finance.yahoo.com

scPharmaceuticals Announces Positive Feedback from Two FDA Meetings on Key Long-Term Growth Initiatives

September 13, 2023 | msn.com

Sizing Up scPharmaceuticals

September 8, 2023 | msn.com

Craig-Hallum Initiates Coverage of scPharmaceuticals (SCPH) with Buy Recommendation

September 5, 2023 | finance.yahoo.com

scPharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference

August 12, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Sientra (SIEN) and scPharmaceuticals (SCPH)

September 29, 2023 | Chaikin Analytics (Ad)

His system isolated NVIDIA - Here's His Next Buy.

Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.

August 10, 2023 | msn.com

scPharmaceuticals GAAP EPS of -$0.36 beats by $0.01, revenue of $1.63M beats by $0.01M

August 10, 2023 | finance.yahoo.com

scPharmaceuticals Inc. Reports Second Quarter 2023 Financial Results and Provides Business Update

August 10, 2023 | finance.yahoo.com

ScPharmaceuticals, Inc. (SCPH) Reports Q2 Loss, Tops Revenue Estimates

August 3, 2023 | finance.yahoo.com

scPharmaceuticals to Announce Second Quarter 2023 Financial Results on Thursday, August 10, 2023

August 1, 2023 | finance.yahoo.com

scPharmaceuticals Announces Positive Type C Meeting Feedback from FDA on Potential Heart Failure Class IV Indication Expansion

July 22, 2023 | markets.businessinsider.com

Maxim Group Keeps Their Buy Rating on scPharmaceuticals (SCPH)

July 19, 2023 | markets.businessinsider.com

The Latest Analyst Ratings for scPharmaceuticals

July 18, 2023 | finance.yahoo.com

scPharmaceuticals, Inc. (SCPH) Loses -21.78% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

June 30, 2023 | msn.com

scPharmaceuticals: Oversold Territory, Drug Launch Still Looks Robust

June 23, 2023 | finance.yahoo.com

scPharmaceuticals Inc. Announces Addition to Russell 2000® and Russell 3000® Indexes

June 13, 2023 | fool.com

scPharmaceuticals (NASDAQ: SCPH)

June 8, 2023 | msn.com

Analyst Ratings for scPharmaceuticals

May 29, 2023 | markets.businessinsider.com

SVB Securities Sticks to Its Buy Rating for scPharmaceuticals (SCPH)

May 20, 2023 | msn.com

scPharmaceuticals: Furoscix Firing On All Cylinders In Q1, Bullish Than Ever

May 15, 2023 | marketwatch.com

Large Volume Wearable Injectors Market Forthcoming Trends and Share Analysis by 2031

May 13, 2023 | marketwatch.com

8-K: scPharmaceuticals Inc.

May 13, 2023 | finance.yahoo.com

scPharmaceuticals Inc. (NASDAQ:SCPH) Q1 2023 Earnings Call Transcript

May 12, 2023 | finanznachrichten.de

scPharmaceuticals, Inc.: scPharmaceuticals Inc. Reports First Quarter 2023 Financial Results and Provides Business Update

See More Headlines

Receive SCPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for scPharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SCPH Company Calendar

Last Earnings: 8/10/2023
Today: 9/29/2023
Next Earnings (Estimated): 11/08/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:SCPH
CUSIP: N/A
CIK: 1604950
Web: www.scpharma.com
Phone: (617) 517-0730
Fax: N/A
Employees: 96
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $19.29
High Stock Price Forecast: $25.00
Low Stock Price Forecast: $13.00
Forecasted Upside/Downside: +170.9%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.33)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-36,840,000.00
Net Margins: N/A
Pretax Margin: -1,209.78%
Return on Equity: -73.77%
Return on Assets: -43.25%

Debt

Debt-to-Equity Ratio: 0.60
Current Ratio: 17.12
Quick Ratio: 16.24

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.11 per share
Price / Book: 3.37

Miscellaneous

Outstanding Shares: 35,860,000
Free Float: 34,179,000
Market Cap: $255.32 million
Optionable: Not Optionable
Beta: 0.18

10 Best Stocks to Own in 2023

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2023 and why they should be in your portfolio.

Get This Free Report

Key Executives

Mr. John H. Tucker (Age 60)
Pres, CEO, Principal Exec. Officer & Director
Comp: $912.2k

Ms. Rachael Nokes (Age 48)
CFO & Principal Accounting Officer
Comp: $496.45k

Mr. Michael D. Hassman
Sr. VP of Technical Operations

Katherine Taudvin
VP of Corp. Affairs & HR

Dr. John Mohr Pharm.D.
Sr. VP of Clinical Devel. & Medical Affairs

Steve Parsons
Sr. VP of Commercial

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

SCPH Stock - Frequently Asked Questions

Should I buy or sell scPharmaceuticals stock right now?: 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for scPharmaceuticals in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SCPH shares.
View SCPH analyst ratings or view top-rated stocks.
What is scPharmaceuticals' stock price forecast for 2023?: 6 analysts have issued twelve-month price objectives for scPharmaceuticals' shares. Their SCPH share price forecasts range from $13.00 to $25.00. On average, they predict the company's share price to reach $19.29 in the next year. This suggests a possible upside of 170.9% from the stock's current price.
View analysts price targets for SCPH or view top-rated stocks among Wall Street analysts.
How have SCPH shares performed in 2023?: scPharmaceuticals' stock was trading at $7.17 at the beginning of the year. Since then, SCPH stock has decreased by 0.7% and is now trading at $7.12.
View the best growth stocks for 2023 here.
When is scPharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our SCPH earnings forecast.
How were scPharmaceuticals' earnings last quarter?: scPharmaceuticals Inc. (NASDAQ:SCPH) released its quarterly earnings data on Thursday, August, 10th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.37) by $0.01. The firm earned $1.64 million during the quarter, compared to the consensus estimate of $1.55 million.
What other stocks do shareholders of scPharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other scPharmaceuticals investors own include Adamas Pharmaceuticals (ADMS), Dynavax Technologies (DVAX), Fulcrum Therapeutics (FULC), ImmunoGen (IMGN), VBI Vaccines (VBIV), Selecta Biosciences (SELB), SCYNEXIS (SCYX), Syndax Pharmaceuticals (SNDX), Sorrento Therapeutics (SRNE) and TG Therapeutics (TGTX).

When did scPharmaceuticals IPO?: (SCPH) raised $96 million in an initial public offering on Friday, November 17th 2017. The company issued 6,400,000 shares at a price of $14.00-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO.
What is scPharmaceuticals' stock symbol?: scPharmaceuticals trades on the NASDAQ under the ticker symbol "SCPH."
How do I buy shares of scPharmaceuticals?: Shares of SCPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is scPharmaceuticals' stock price today?: One share of SCPH stock can currently be purchased for approximately $7.12.
How much money does scPharmaceuticals make?: scPharmaceuticals (NASDAQ:SCPH) has a market capitalization of $255.32 million. The company earns $-36,840,000.00 in net income (profit) each year or ($1.33) on an earnings per share basis.
How can I contact scPharmaceuticals?: scPharmaceuticals' mailing address is 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA, 01830. The official website for the company is www.scpharma.com. The company can be reached via phone at (617) 517-0730 or via email at tignelzi@scpharma.com.

This page (NASDAQ:SCPH) was last updated on 9/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial